The Bacteriophage Therapy Market Is Estimated To Witness High Growth Owing To Increasing Prevalence of Antibiotic-Resistant Infections & Growing Investments in Research and Development

1
The Bacteriophage Therapy Market Is Estimated To
Witness High Growth Owing To
Increasing Prevalence of Research and
Development
Antibiotic-Resistant
Infections

Growing
Investments
in
A) Market Overview The global Bacteriophage
Therapy Market is estimated to be valued at
US1,148.6 million in 2020 and is expected to
exhibit a CAGR of 3.7 over the forecast period
2020-2030, as highlighted in a new report
published by Coherent Market Insights.
Bacteriophage therapy involves the use of
viruses (bacteriophages) to target and destroy
specific bacteria, offering a potential
alternative to antibiotics. It has shown
promising results in treating antibiotic-resistant
infections such as MRSA, E. coli, and
Pseudomonas aeruginosa. This therapy is
considered safe, effective, and has minimal side
effects, making it a key focus area for research
and development.
B) Market Dynamics The Bacteriophage Therapy
Market is driven by two main factors. Firstly,
the increasing prevalence of antibiotic-resistant
infections is propelling the demand for
alternative treatments. Antibiotic resistance
has become a global healthcare crisis, leading to
a rise in healthcare- associated infections that
are difficult to treat. Bacteriophage therapy
offers a solution by targeting specific bacteria
without harming the body's normal flora.
Secondly, growing investments in research and
development are fueling the market growth.
Pharmaceutical companies and research
institutions are investing heavily in developing
new phage-based therapies and conducting clinical
trials to establish their safety and efficacy.
2
C) Market Key Trends One key trend in the
Bacteriophage Therapy Market is the use of
personalized phage therapy. Traditionally, phage
therapy involved using pre-selected phages to
treat infections. However, recent advancements
in genomics and bioinformatics have enabled the
identification and isolation of personalized
bacteriophages tailored to a specific patient's
infection. Personalized phage therapy has shown
promising results in treating multidrug-resistant
infections and is expected to gain traction in
the market.
D) SWOT Analysis - Strengths Specific
targeting of bacteria, minimal side effects -
Weaknesses Limited regulatory framework, lack of
standardized production methods -
Opportunities Rising investments in RD, growing
awareness about antibiotic resistance -
Threats Uncertainty in regulatory approvals,
competition from alternative therapies
E) Key Takeaways
The global Bacteriophage Therapy Market is
expected to witness high growth,
-
exhibiting a CAGR of 3.7 over the forecast
period, due to increasing prevalence
of antibiotic-resistant infections and growing
investments in research and development. North
America is the fastest-growing and dominating
region in the market, driven by the presence of
major pharmaceutical companies, well-established
healthcare infrastructure, and high prevalence
of antibiotic-resistant infections. Key players
operating in the global Bacteriophage Therapy
Market include Armata Pharmaceuticals, Inc.,
Eliava Biopreparations Ltd., Pherecydes Pharma,
Intralytix, Inc., Phagelux, Inc., Nextbiotics,
InnoPhage Ltd, and more. These companies are
actively involved in research and development
activities to develop novel phage therapies and
expand their product portfolio.
-
-
In conclusion, the rising prevalence of
antibiotic-resistant infections and increasing
investments in research and development are
driving the growth of the bacteriophage therapy
market. With its ability to specifically target
bacteria and minimal side effects, bacteriophage
therapy holds great potential as an alternative
treatment option for antibiotic-resistant
infections. However, challenges such as limited
regulatory framework and competition from
alternative therapies need to be addressed to
fully realize the market's potential.